Alendronate sodium hydrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Alendronate sodium hydrate (Alendronate;MK 217;G-704650 Adronat) is a bisphosphonate that acts as a specific inhibitor of osteoclastmediated bone resorption.

Alendronate sodium hydrate (Alendronate;MK 217;G-704650 Adronat) is a bisphosphonate that acts as a specific inhibitor of osteoclastmediated bone resorption, inhibits osteoclast protein-tyrosine phosphatase (PTPepsilon) with IC50 of 2 uM; also inhibits the activities of other bacterially expressed PTPs such as PTPsigma and CD45, suppresses in vitro formation of multinucleated osteoclasts from osteoclast precursors and in vitro bone resorption by isolated rat osteoclasts with IC50 of 10 uM; also is also inhibits farnesyl disphosphate synthase with IC50 of 1.7 uM.Osteoporosis Approved

Alendronate;MK 217;G-704650 Adronat

Others

Other Targets

Farnesyldiphosphatesynthase

Metabolic Disease

Osteoporosis

121268-17-5

325.12

C4H18NNaO10P2

>98% (HPLC)

H2O: ≥ 28.57 mg/mL; DMSO: < 3.2 mg/mL

OC(P([O-])(O)=O)(P(O)(O)=O)CCCN.[H]O[H].[H]O[H].[H]O[H].[Na+]

Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt, hydrate (1:1:3)

(-20℃)

With Ice Pack

≥ 2 years